ROC-325 is a novel, potent and orally bioactive autophagy inhibitor with potent anticancer activity. ROC-325 exhibited superior in vitro anticancer effects compared with the existing autophagy inhibitor hydroxychloroquine (HCQ) in 12 different cancer cell lines with diverse genetic backgrounds. ROC-325 antagonized RCC growth and survival in an ATG5/7-dependent manner, induced apoptosis, and exhibited favorable selectivity.

纯度：≥98%

CAS：1859141-26-6